Vaccine for herpes simplex type 2 (HSV-2) virus awarded innovation passport in the UK

The designation was awarded for RVx201, a live-attenuated therapeutic vaccine that is modified to be interferon sensitive and destroy the ability of the virus to inhibit immune responses, being developed for genital herpes resulting from the herpes simplex type 2 (HSV-2) virus.

SPS commentary:

Rational Vaccines is currently in the process of preparing an Investigational Medicinal Product Dossier (IMPD) to the MHRA for a phase Ib/2a trial in the U.K. The company is also advancing RVx201 as a prophylaxis under NIH-funded research.


Innovation Passport is a designation under the Innovative Licensing and Access Pathway (ILAP), which was launched by the MHRA in January 2021 to reduce the time to market for innovative medicines.


Biospace Inc.